All articles by
BMS’s SC Opdivo shows noninferiority against IV Opdivo in Phase 3 ccRCC trial
The CheckMate -67T trial showed that the subcutaneous nivolumab demonstrated noninferior pharmacokinetics and objective response rate compared to intravenous Opdivo
Pathos AI Completes Acquisition of Rain Oncology
Rain Stockholders to Receive $1.16 Per Share in Cash Plus Contingent Value Rights
Four-dose Mounjaro “KwikPen” approved by MHRA for diabetes and weight management
The new presentation of Mounjaro gives four doses for once-a-week treatment over a month
Time matters for antimicrobial treatment
Antimicrobial resistance is an ongoing threat to patients the longer they stay in hospital. Tiziana Di Martino, chief medical officer at Q-linea, explains how her company’s new ASTar system, which Thermo Fisher Scientific will be distributing globally, helps tackle the problem.
The future of laboratory automation
Quickly understanding a patient’s condition is crucial to keeping public health ticking over – but that can be tough without robust diagnostic tests. Nicolas Quoix, EU senior marketing manager at Beckman Coulter Diagnostics, explains what his company can offer.
Sandoz to buy Cimerli business from Coherus for $170m
The acquisition is expected to strengthen Sandoz’s ophthalmology portfolio in the US and includes the BLA, product inventory, ophthalmology sales and field reimbursement staff, and access to proprietary commercial software
Virios to advance development of combination therapy for long Covid
IMC-2 is a combination of valacyclovir and celecoxib and its Phase 2 programme is expected to start in the second half of this year, with data expected by 2025
MHRA introduces new restrictions for fluoroquinolone antibiotics
The MHRA conducted a thorough review into the effectiveness of current measures to reduce the risk of potentially long-term adverse reactions to fluoroquinolone antibiotics and sought advice from the Commission on Human Medicines
UK’s NICE recommends talazoparib for treatment of advanced breast cancer
The decision from NICE marks a shift from its previous preliminary stance of not supporting the use of talazoparib for adults with BRCA 1 or 2 mutated HER2-negative locally advanced or metastatic breast cancer post-chemotherapy, and has been driven after Pfizer offered an increased discount on the drug
Uni-Bio secures China’s NMPA marketing approval for Bogutai injection
Bogutai, created in partnership with the Swiss company Ypsomed, features a pre-filled structural design and is intended for osteoporosis treatment in postmenopausal women at high risk of fractures